Durvalumab
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oral Cavity Squamous Cell Carcinoma
Conditions
Oral Cavity Squamous Cell Carcinoma
Trial Timeline
Aug 27, 2018 → Mar 24, 2026
NCT ID
NCT03784066About Durvalumab
Durvalumab is a phase 1/2 stage product being developed by AstraZeneca for Oral Cavity Squamous Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03784066. Target conditions include Oral Cavity Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06992609 | Phase 3 | Recruiting |
| NCT06826677 | Pre-clinical | Completed |
| NCT05925530 | Phase 2 | Active |
| NCT04944173 | Phase 2 | Withdrawn |
| NCT05924880 | Phase 3 | Completed |
| NCT05617963 | Phase 2 | Recruiting |
| NCT05683977 | Pre-clinical | Active |
| NCT05303532 | Phase 3 | Recruiting |
| NCT05215106 | Phase 2 | Recruiting |
| NCT04416633 | Approved | Completed |
| NCT05933044 | Pre-clinical | Completed |
| NCT04765709 | Phase 2 | Terminated |
| NCT04667312 | Pre-clinical | Completed |
| NCT04062708 | Phase 2 | Active |
| NCT04230408 | Phase 2 | Completed |
| NCT04441138 | Phase 2 | Terminated |
| NCT05267392 | Phase 1/2 | UNKNOWN |
| NCT04543110 | Phase 2 | UNKNOWN |
| NCT04716946 | Phase 2 | Active |
| NCT04642469 | Phase 3 | Completed |
Competing Products
20 competing products in Oral Cavity Squamous Cell Carcinoma